What question did this study set out to answer?

The research aims to assess the burden of illness and hematocrit control in high- and low-risk polycythemia vera patients under current treatment standards.

December 8, 2025BloodOpen Access

Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States

View Full Paper

Ask AI

Bookmark

Authors

AFAnna M. Fan ACAlicia Cerretani

Discussion

Member takes

Overview

Analysis shows sub-optimal disease management in high-risk and low-risk polycythemia vera patients, indicating treatment gaps.

Key Points

The research aims to assess the burden of illness and hematocrit control in high- and low-risk polycythemia vera patients under current treatment standards.
Identified patients with polycythemia vera diagnosis from MarketScan databases between 2011-2022.
Categorized patients as high-risk or low-risk based on age and thrombotic events.
Analyzed treatment patterns, clinical outcomes, and costs following treatment and thrombotic events.
11,311 patients included: 5,859 high-risk (mean age 68.3) and 5,452 low-risk (mean age 48.9).
Significant sub-optimal disease management found in both groups (52.6% high-risk, 49.1% low-risk).
Higher occurrence of thrombotic events in high-risk patients (21.3% vs. 9.0% low-risk).

Cite This Study

Fan et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cf92 https://doi.org/10.1182/blood-2025-2854

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States

View Full Paper

Ask AI

Bookmark

Authors

AFAnna M. Fan ACAlicia Cerretani

Discussion

Member takes

Overview

Analysis shows sub-optimal disease management in high-risk and low-risk polycythemia vera patients, indicating treatment gaps.

Key Points

The research aims to assess the burden of illness and hematocrit control in high- and low-risk polycythemia vera patients under current treatment standards.
Identified patients with polycythemia vera diagnosis from MarketScan databases between 2011-2022.
Categorized patients as high-risk or low-risk based on age and thrombotic events.
Analyzed treatment patterns, clinical outcomes, and costs following treatment and thrombotic events.
11,311 patients included: 5,859 high-risk (mean age 68.3) and 5,452 low-risk (mean age 48.9).
Significant sub-optimal disease management found in both groups (52.6% high-risk, 49.1% low-risk).
Higher occurrence of thrombotic events in high-risk patients (21.3% vs. 9.0% low-risk).

Cite This Study

Fan et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cf92 https://doi.org/10.1182/blood-2025-2854

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark